BRCA2 and breast carcinoma: Furthermore, 30% of breast cancer patients without heredity were found to have methylation of the BRCA1 and BRCA2 promoter or dysfunctional upstream pathways, leading to descending levels of BRCA1 and BRCA2 (10, 11).